Medical imaging service provider Median Technologies and Microsoft announced a joint global initiative in the rapidly growing precision medicine market to develop new cancer detection, diagnosis and monitoring methods using big-data analytics.
As part of the initiative, Median will install its imaging biomarker phenotyping system (IBIOPSY) on the Microsoft Azure cloud computing platform. On Azure, IBIOPSY will provide capabilities for processing and analyzing medical images, extracting biomarkers of disease in real time for cancer diagnosis and treatment purposes.
IBIOPSY will eventually be made available to medical facilities and physicians in the U.S., Europe, and Asia to meet the image processing and data analytics needs created by the next generation of personalized cancer therapies and the explosive growth in medical imaging data.
The two companies plan to work together to help medical centers take advantage of Azure. They also will focus on the development of novel predictive analytics methods based on machine learning and encryption capabilities that will be available on Azure, according to a press statement.
Founded in 2002, Median Technologies is based in Sophia-Antipolis, France, and has a U.S. subsidiary in Boston.